Executive Summary of the II Brazilian Guidelines for Atrial Fibrillation

Magalhães, Luiz Pereira de; Figueiredo, Márcio Jansen de Oliveira; Cintra, Fátima Dumas; Saad, Eduardo; Kuniyoshi, Ricardo; Filho, Adalberto Menezes Lorga; d’Ávila, André; Paola, Ângelo Amato Vincenzo de; Kalil, Carlos; Moreira, Dalmo Antônio Ribeiro; Filho, Dário Celestino Sobral; Sternick, Eduardo Back; Darrieux, Francisco; Fenelon, Guilherme; Lima, Gustavo Glotz de; Atié, Jacob; Mateos, José Carlos Pachón; Moreira, José Marcos; Vasconcelos, José Tarcísio Medeiros de; Zimerman, Leandro Ioschpe; Silva, Luiz Roberto Leite da; Silva, Márcio Augusto; Scanavacca, Maurício; Souza, Olga Ferreira de

doi:10.5935/abc.20160190

Cited by 19 publications

(29 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NOAC use is likely to increase in coming years, given their favorable safety and efficacy profile, as guidelines are updated . The new Brazilian Guideline from 2016 and Mexican Guidelines, for example, indicates the use of NOACs in a similar manner to the European guidelines. This has also been stressed by different groups of Latin American investigators …”

Section: Discussionmentioning

confidence: 99%

Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

Jerjes‐Sánchez

Corbalán

Barretto

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Background Atrial fibrillation (AF) is an important preventable cause of stroke. Anticoagulation (AC) therapy can reduce this risk. However, prescribing patterns and outcomes in patients with non‐valvular AF (NVAF) from Latin American countries are poorly described. Methods Using data from the Global Anticoagulant Registry in the FIELD‐AF (GARFIELD‐AF), we examined the stroke prevention strategies and the 1‐year outcomes in patients from four Latin American countries: Argentina, Brazil, Chile, and Mexico. Results A total of 4162 patients (2010‐2014) were included in this analysis. At the time of AF diagnosis, 39.9% of patients were prescribed vitamin K antagonists (VKA) ± antiplatelet (AP) therapy, 21.8% non‐VKA oral anticoagulant (NOAC) ± AP, 24.1% AP only and 14.1% no antithrombotic treatment. The proportion of moderate‐high risk patients receiving no AC therapy at participating centers was highest in Mexico (46.4%) and lowest in Chile (14.3%). During 1‐year follow‐up, the rates of all‐cause mortality, stroke/SE and major bleeding were: 5.77 (95% CI) (5.06‐6.56), 1.58 (1.23‐2.02), and 0.99 (0.72‐1.36) and per 100 person‐years, respectively, which are higher than the global rates across all countries in GARFIELD‐AF. Unadjusted rates of all‐cause mortality were highest in Argentina, 6.95 (5.43‐8.90), and lowest in Chile, 4.01 (2.92‐5.52). Conclusions GARFIELD‐AF results describes the marked variation in the baseline characteristics and patterns of antithrombotic treatments in patients with NVAF in four Latin American countries. Over one‐third of patients with a moderate‐to‐high risk of stroke received no AC therapy, highlighting the need for improved management of patients according to national guideline. Clinical Trial Registration—URL http://www.clinicaltrials.gov. Unique identifier: NCT01090362.

show abstract

Section: Discussionmentioning

confidence: 99%

Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

Jerjes‐Sánchez

Corbalán

Barretto

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…According to the 2010 Global Burden of Disease Study, approximately 33 million people around the world suffer from AF, [ 1 ] leading to a heavy economic burden on society. [ 2 ] At present, although there are a variety of options for the treatment of AF, such as antiarrhythmic medication, surgical ablation, and catheter ablation, [ 3 – 5 ] catheter ablation is used as the first-line therapy by doctors and patients, [ 6 , 7 ] and it is increasingly being chosen as a therapeutic strategy for AF. [ 8 ] It is well known that AF recurrence is very common after catheter ablation and may decrease the probability of long-term success.…”

Section: Introductionmentioning

confidence: 99%

Are left ventricular ejection fraction and left atrial diameter related to atrial fibrillation recurrence after catheter ablation?

Jin

Pan

et al. 2018

Medicine

View full text Add to dashboard Cite

Atrial fibrillation (AF), the most common form of arrhythmia, is associated with the prevalence of many common cardiovascular and cerebrovascular diseases. Catheter ablation is considered the first-line therapy for AF; however, AF recurrence is very common after catheter ablation. Studies have been performed to analyze the factors associated with AF recurrence, but none have reached a consistent conclusion on whether left ventricular ejection fraction (LVEF) and left atrial diameter (LA diameter) affect AF recurrence after catheter ablation.The databases PubMed, Embase, and the Cochrane Library were used to search for relevant studies up to September 2017. RevMan 5.3.5 software provided by the Cochrane Collaboration Network was used to conduct this meta-analysis.Thirteen studies involving 2825 patients were included in this meta-analysis. Overall, the results revealed that elevated LA diameter values were significantly associated with AF recurrence in patients after catheter ablation (MD = 2.19, 95% CI: 1.63–2.75, P < .001), while baseline LVEF levels were not significantly positively associated with AF recurrence in patients after catheter ablation (MD = −0.91, 95% CI: −1.18 to 1.67, P = .14).Overall, elevated LA diameter may be associated with AF recurrence after catheter ablation; however, there was no direct relationship between LVEF values and AF recurrence after catheter ablation when baseline LVEF values are normal or mildly decreased. Besides, because of publication bias, further studies should be performed to explore the mechanisms underlying AF recurrence.

show abstract

“…Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in the world [1]. Its prevalence is almost twice as high as the observed in the past decade, but data about AF may be underestimated because the asymptomatic form is not diagnosed frequently [2]. AF is associated with a mortality increase of approximately two times that observed among patients with sinus rhythm [3].…”

Section: Introductionmentioning

confidence: 99%

“…AF genesis is related to electrophysiological alterations in the atrial tissue that foster and propagate the abnormal electric impulse. Many clinical conditions are considered risk factors for the development of AF, and possibly influence in the prevalence rise observed in the last decades [2].…”

Section: Introductionmentioning

confidence: 99%

How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.

show abstract

Executive Summary of the II Brazilian Guidelines for Atrial Fibrillation

Cited by 19 publications

References 71 publications

Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

Are left ventricular ejection fraction and left atrial diameter related to atrial fibrillation recurrence after catheter ablation?

How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?

Contact Info

Product

Resources

About